Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue: +51.9%
EPS: +73.9%
Free cash flow: −1,078.3%
Total debt: +4.04%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

132.13 2.33 +1.80%

Follow AXSM

Alert me

Market cap: $6.8B
P/E: 0.0×
Fwd P/E: −49.2×
Dividend yield: —
F-score: 5/9
Altman Z: 6.91
Beneish M: −2.53
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Axsome Therapeutics, Inc. (AXSM) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Axsome Therapeutics, Inc. (AXSM) trades at a P/B ratio of 64.2×. Over the past ten years it has ranged from 0.0× (December 2015) to 536× (December 2019); the current reading is higher than 70% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/AXSM/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Axsome Therapeutics, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/AXSM/metrics/pb-ratio">Axsome Therapeutics, Inc. (AXSM) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	103×	44.72%
FY2024	71.1×	287.93%
FY2023	18.3×	(32.64%)
FY2022	27.2×	—

Period	P/B ratio	Change
Sep 2026	91.7×	(39.74%)
Jun 2026	152×	(3.99%)
Mar 2026	159×	54.05%
Dec 2025	103×	24.88%
14 more quarters	Free account

Against its own ten years

Low 0.0× High 536×

Ten-year median 23.6×

Current reading's percentile 70

Company	P/B ratio
MIRM Mirum Pharmaceuticals, Inc. compare	n/m
ORKA Oruka Therapeutics, Inc. compare	5.5×
PRAX Praxis Precision Medicines, Inc. compare	5.7×
LGND Ligand Pharmaceuticals Incorporated compare	6.2×
BLTE Belite Bio, Inc. Sponsored ADR compare	7.5×
IONS Ionis Pharmaceuticals, Inc. compare	14.6×
ABVX Abivax SA Sponsored ADR compare	15.8×
AXSM Axsome Therapeutics, Inc.	64.2×
RYTM Rhythm Pharmaceuticals, Inc. compare	81.4×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Axsome Therapeutics, Inc. (AXSM) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on AXSM

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on AXSM

Stockrow Weekly